Cornyn Questions Blanche on Trump IRS Settlement and Unmodified Weaponization Fund
Source: THE PUBLIC BRIEF_101 · All THE PUBLIC BRIEF_101 reports
Unlock the full scoreboard
Letter grade, factuality, lean, and rationales — free with registration. No card required.
See grades free How grading works
Already have an account? Sign in. The full report below is free to read.
Embed this grade
Disagree with this grade or political lean?
Flagging is open to every reader with a free account. Sign in or create one to dispute this report.
Topics in this report
Summary
Senator John Cornyn questioned acting Attorney General nominee Todd Blanche during what appears to be a Senate confirmation hearing. The discussion centered on the unusual May 2026 settlement of President Trump's $10 billion lawsuit against the IRS and Treasury over the 2019-2020 leak of his tax returns by contractor Charles Littlejohn. Cornyn raised concerns about the two-year statute of limitations on the 2020 leak, the creation of a $1.776 billion 'anti-weaponization fund,' the scope of a release barring IRS audits of Trump, his family, and affiliates for prior returns, and vague language around 'lawfare or weaponization.' Blanche maintained the fund was never operational, received no Treasury money, and is effectively dead, while defending the release as standard IRS settlement language limited to the IRS and Treasury. The exchange also touched on the separate Louisiana v. FDA mifepristone case, with Cornyn urging Blanche to respond to a letter on restoring in-person dispensing requirements.
Sourcing relied on the text of the settlement agreement (read aloud by Cornyn), prior hearing statements by Blanche and Sen. Durbin, and a chart of the May 19, 2026 release document. No outside experts or opposing witnesses appeared; the segment is a direct excerpt of the Cornyn-Blanche colloquy.
Editorial Assessment
The hearing segment accurately reflects documented controversies surrounding the Trump IRS settlement, including legal challenges over self-dealing, the fund's potential to compensate January 6 defendants, and sweeping audit immunity that tax experts called unprecedented. Cornyn correctly notes the agreement's modification clause requires written consent of all parties, which had not occurred at the time of the hearing despite Blanche's assurances the fund 'is dead' and 'not moving forward.' Later reporting indicates Blanche issued written rescissions to satisfy Cornyn and Sen. Tillis, narrowing the immunity to plaintiffs and making it retroactive only. Viewers miss the full context that federal judges had questioned the lawsuit's propriety given Trump's control of the defendant agencies and that the fund faced multiple lawsuits alleging it violated the Appropriations Clause. The mifepristone portion accurately summarizes medical literature on risks but frames Biden-era changes as removing 'all medical guidance,' which overstates the FDA's REMS modifications allowing certified pharmacies and telehealth in some cases. Overall, the clip gives a Republican critique of a Trump-era deal without exploring Democratic arguments that it constitutes a taxpayer-funded reward for political allies.
Key Moments
The IRS contractor Charles Littlejohn leaked Trump tax returns in 2020; Trump was a victim of a crime, but the lawsuit was filed in 2026 beyond the two-year statute of limitations.
Littlejohn leaked in 2019-2020, pleaded guilty in 2023, and was sentenced to five years; the 26 U.S.C. § 7431 two-year discovery rule is correctly cited, though plaintiffs argued delayed discovery.
The settlement agreement created a weaponization fund that remains unmodified in writing and is an enforceable contract that could theoretically be enforced by plaintiffs.
The May 2026 agreement established a $1.776B fund modifiable only in writing by all parties; Blanche conceded it was enforceable but said the fund never received money and was not moving forward.
The release applies only to plaintiffs in the lawsuit, binds only the IRS/Treasury, and does not cover other agencies like the SEC.
The document language is broad, extending to 'related or affiliated individuals' including family, trusts, and subsidiaries; later clarifications by Blanche limited it, but the original text prompted bipartisan criticism.
Mifepristone is a chemical abortion drug usable up to 10 weeks; Biden changes allowed administration without medical guidance, leading to complications like heavy bleeding and incomplete abortion.
FDA data and literature confirm risks but also overall safety under REMS; the 2023 changes expanded pharmacy certification and telehealth prescribing, not complete removal of oversight; ongoing Louisiana v. FDA litigation challenges these.
The terms 'lawfare' and 'weaponization' in the release are not legal terms of art defined in any statute or case.
Blanche agreed they are not in Black's Law Dictionary or statutes; their meaning would depend on specific facts, leaving the release's scope ambiguous.
Notable Concerns
- The settlement's audit release and fund were widely criticized across party lines as creating conflicts of interest and potential slush-fund mechanisms, context largely omitted here.
- Vague 'lawfare and weaponization' terms in the release lack statutory or case-law definition, as both parties acknowledged, raising enforceability questions.
- Timing of the 2026 lawsuit relative to the 2020 disclosures raises legitimate statute-of-limitations issues under 26 U.S.C. § 7431, though plaintiffs pled a discovery rule.
Sources Consulted
- Trump’s IRS settlement agreement, annotated
- Blanche’s Documents Addressing Trump I.R.S. Deal Leave Loopholes
- Trump drops IRS lawsuit in exchange for DOJ $1.8 billion 'weaponization' fund
- Cornyn, Tillis Urge Blanche to Protect Life, Counter Dangerous Mail-Order Abortion Drugs
- Justice Department considers settling Trump’s $10 billion IRS leak lawsuit
- D.C. Circuit Upholds 5-Year Sentence for Leaker of Trump's and Others' Tax Returns
- As Blanche's Path to Confirmation Is Cleared, Trump's Tax Audit Immunity Remains in Place